17. 多系統萎縮症 Multiple system atrophy Clinical trials / Disease details


臨床試験数 : 119 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03753763
(ClinicalTrials.gov)
October 29, 201919/11/2018Safinamide for Multiple System Atrophy (MSA)12-weeks, Multicentre, Randomized, Double-blind, Placebo-controlled, Exploratory, Pilot Study to Evaluate the Safety and Efficacy of Safinamide 200 mg OD, as add-on Therapy, in Patients With Possible or Probable Parkinsonian Variant of MSAMultiple System AtrophyDrug: Safinamide Methanesulfonate;Drug: Safinamide Methanesulfonate matching placeboZambon SpANULLCompleted30 Years80 YearsAll49Phase 2Italy;Spain
2EUCTR2018-004145-16-ES
(EUCTR)
24/07/201911/06/2019A study evaluating the safety and efficacy of safinamide for patients with Multiple System AtrophyA 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients with possible or probable parkinsonian variant of multiple system atrophy. - Safinamide for Multiple System Atrophy Parkinsonian variant of Multiple System Atrophy
MedDRA version: 20.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Xadago
INN or Proposed INN: safinamide methanesulfonate
Other descriptive name: SAFINAMIDE
Zambon SpANULLNot RecruitingFemale: yes
Male: yes
48Phase 2Spain;Italy